US EditionEli Lilly to Start Late-Stage Trials on Amylin Obesity Drug After It Shows up to 20% Weight Loss in Study
Eli Lilly's drug eloralintide mimics pancreatic hormone amylin to suppress hunger and slow digestion, achieving up to 20.1% weight loss in mid-stage trials, offering a new obesity treatment option.
- On Nov. 6, 2025, Eli Lilly and Company announced it will start late-stage enrollment next month after positive Phase 2 results for eloralintide.
- Amylin analogs mimic a pancreatic hormone to suppress appetite and slow digestion, and analysts say they offer an alternative or complement to GLP-1 drugs, attracting investments from Roche, AbbVie, and Novo Nordisk.
- The randomized trial of 263 adults showed meaningful dose-dependent reductions, with eloralintide 9 mg producing 20.1% mean weight loss and lower arms yielding 9.5% at 48 weeks.
- The trial reported mostly mild gastrointestinal side effects and fatigue, slower dose escalation reduced those events, treatment improved cardiometabolic markers, and Lilly shares rose nearly 2%.
- By the end of this year, Lilly plans to initiate Phase 3 clinical studies and begin enrollment next month, having presented results at ObesityWeek and published them in The Lancet with cautionary statements on risks.
14 Articles
14 Articles
Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive results from a Phase 2 trial evaluating the safety and efficacy of eloralintide, an...
Amylin Analog Eloralintide Reduces Weight in Phase 2 Trial
Stepped dose titration improved tolerability. Medscape Medical News Source link : https://www.medscape.com/viewarticle/amylin-analog-eloralintide-reduces-weight-phase-2-trial-2025a1000uqf?src=rss Author : Publish date : 2025-11-06 21:41:00 Copyright for syndicated content belongs to the linked Source. The post Amylin Analog Eloralintide Reduces Weight in Phase 2 Trial first appeared on News Health.
Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study – DG Verifications & Stats
In this article LLY Follow your favorite stocksCREATE FREE ACCOUNTEli Lilly Biotechnology Center is shown in San Diego, California, March 1, 2023.Mike Blake | Reuters Eli Lilly on Thursday said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging results in a mid-stage study. The highest dose of the weekly injection, called eloralintide, helped patients with obesity or who are overweight…
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
